Question special
Faculty Member

I am wondering if/how investigators adjusted doses of AR101 if a subject experienced a treatment-associated reaction during the up-dosing period. Were doses reduced by 1-2 doses or maintained for an additional period of time? Additionally, for subjects with asthma who required systemic steroids for an asthma flare during up-dosing or during maintenance, was the AR101 dose affected in any way?